Ed Esplin, SVP of Medical Affairs at Biocartis, shared on LinkedIn:
“~1/6 Patients across 32 cancer types had pathogenic germline variants (PGVs) on germline testing (inc. prostate, lung, kidney, sarcoma etc.)
72% of patients w/ a PV would have been missed by a strict age cutoff of <50 yrs as rec’d by many guidelines.
Clinically actionable germline findings have important implications for treatment, surveillance, and cascade testing.
Universal germline and tumor genomic testing needed to win the war against cancer.
These data support universal germline genetic testing for all individuals diagnosed w/ cancer.”
Title: Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome
Authors: N. Jewel Samadder, Douglas Riegert-Johnson, Lisa Boardman, Deborah Rhodes, Myra Wick, Scott Okuno, Katie L. Kunze, Michael Golafshar, Pedro L. S. Uson Jr, Luke Mountjoy, Natalie Ertz-Archambault, Neej Patel, Eduardo A. Rodriguez, Blanca Lizaola-Mayo, Michael Lehrer, Cameron S. Thorpe, Nathan Y. Yu, Edward D. Esplin, Robert L. Nussbaum, Richard R. Sharp, Cindy Azevedo, Margaret Klint, Megan Hager, Sarah Macklin-Mantia, Alan H. Bryce, Tanios S. Bekaii-Saab, Aleksandar Sekulic, A. Keith Stewart.
Title: Universal Germline Genetic Testing after a Diagnosis of Cancer
Authors: Zsofia K. Stadler, Anna Maio, Aliya Khurram, Kanika Arora, Chaitanya Bandlamudi, Ying L. Liu, Yelena Kemel, Margaret Sheehan, Erin Salo-Mullen, Angelika Padunan, Tina Alano, William D. Tap, Julia L. Glade Bender, Andrea Cercek, Ingo K. Mellinghoff, Eileen M. O’Reilly, Alan L. Ho, Michael D. Offin, Alexander N. Shoushtari, Chimene A. Kesserwan, Mohammad Abbass, Lauren Banaszak, Lisa M. DeAngelis, Yonina R. Murciano-Goroff, Marc Ladanyi, Ozge Ceyhan-Birsoy, Maria I. Carlo, Alicia Latham, Mark E. Robson, David B. Solit, Michael F. Berger, Diana L. Mandelker, Kenneth Offit, Luis A. Diaz Jr.
Title: Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis
Authors: Vivek Subbiah, Razelle Kurzrock.
Other articles about Ed Esplin on OncoDaily.